In this session, Meng Li sets out estimates of real option value for drugs arguing that option value matters and can be calculated. Adrian Towse sets out likely payer concerns about incorporating real option value into decision making. Meng Li responds to these concerns. Jens Grueger sets out how industry considers investment opportunities, arguing that if patients (and society) have preferences these need to be reflected in P&R decisions.
Author(s) and affiliation(s): Meng Li, Postdoctoral Research Fellow, Leonard D Schaeffer Center, University of Southern California, Los Angeles, CA, USA. Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Jens Grueger, formerly Head of Global Access, Senior Vice President at F. Hoffmann-La Roche
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Real option value drugs: is it really an option?
1. ohe.org
PRESENTATOINISPOR*NEW*ORLEANS
Real option value drugs:
is it really an option?
BREAKOUT*SESSION*6:*IP16
Adrian*Towse
Emeritus*Director*and*Senior*Research*Fellow
Visting*Professor,*London*School*of*Economics*
21ST
MAY(2019
2. Real option value drugs: is it really an option?
ISPOR&NEW&ORLEANS IP16
2
21ST MAY(2019
●Meng Li, PhD, ScM, Postdoctoral Research Fellow, Leonard D Schaeffer
Center, University of Southern California, Los Angeles, CA, USA.
●Meng will set out estimates of real option value for three drugs and arguing
that option value matters and can be calculated.
●Adrian Towse, MA, MPhil, Emeritus Director and Senior Research Fellow,
Office of Health Economics
●Adrian will set out likely payer concerns about incorporating real option value
into decision making.
●Jens Grueger, formerly Head Global Access, Senior Vice President at F.
Hoffmann - La Roche
●Jens will set out how industry considers investment opportunities, arguing that
if patients (and society) have preferences these need to be reflected in P&R
decisions.